抗血管内皮生长因子玻璃体内注射治疗不同区域早产儿视网膜病变的疗效观察

发布时间：2018-04-08 15:13

  本文选题：早产儿视网膜病变　切入点：抗血管内皮生长因子药物　出处：《眼科新进展》2017年05期

【摘要】：目的观察抗血管内皮生长因子(vascular endothelial growth factor,VEGF)治疗不同区域早产儿视网膜病变的临床效果。方法回顾性分析2013年4月至2014年4月在郑州儿童医院行玻璃体内注射抗VEGF药物的早产儿视网膜病变患儿24例(46眼),分为Ⅰ区病变组15例(28眼),Ⅱ区病变组9例(18眼)。所有患者均在全身麻醉下行玻璃体内注射抗VEGF药物雷珠单抗,对患儿术后眼底进展情况进行观察,分析两组首次注射治愈和进展情况以及并发症发生情况。结果两组间的出生孕周、出生体质量相比,差异均无统计学意义(均为P0.05);手术矫正孕周相比,差异有统计学意义(P=0.001)。24例(46眼)中,首次注射治愈21眼,病情继续发展25眼,治愈率为45.65%,治疗到治愈的时间间隔为2~12个月。Ⅰ区病变组首次注射治愈9眼,治愈率为32.14%,进展率为67.86%;Ⅱ区病变18眼中12眼首次注射治愈,6眼病情继续进展,治愈率为66.67%,进展率为33.34%。两组首次注射治愈率相比,差异有统计学意义(χ~2=5.263,P=0.022),Ⅰ区病变的首次注射治愈率明显低于Ⅱ区病变。两组进展率相比,差异有统计学意义(χ~2=-2.269,P=0.023),Ⅰ区病变的进展率明显高于Ⅱ区病变。随访中未发现与玻璃体内注射有关的白内障、眼内炎、视网膜裂孔等出现,仅有2例出现角膜水肿,4例出现结膜下出血,均未做特殊处理自愈。结论玻璃体内注射抗VEGF药物对于Ⅰ区、Ⅱ区病变均有效,Ⅰ区病变手术成功率低,再次手术的几率大,但可为再次手术创造时间和条件。
[Abstract]:Objective to observe the clinical effect of vascular endothelial growth factor (VEGF) on retinopathy of premature infants in different regions.Methods from April 2013 to April 2014, 24 children with retinopathy of preterm infants who received intravitreous injection of anti- VEGF drugs in Zhengzhou Children's Hospital were retrospectively analyzed. The patients were divided into 15 patients (28 eyes) and 9 patients (18 eyes).All patients were given intravitreous injection of anti-#en0# drug Lei Zhu McAb under general anesthesia to observe the fundus progress after operation and to analyze the first injection of cure and progression and the occurrence of complications in the two groups.Results there was no significant difference in birth weight and birth weight between the two groups (all P0.05A, and the difference was statistically significant in 24 patients (46 eyes).) 21 eyes were cured by the first injection and 25 eyes continued to develop.The cure rate was 45.65 and the interval between treatment and cure was 2 ~ 12 months. In the group 鈪，

本文编号：1722160